Y-27632, a ROCK-Inhibitor, Is Now Commercially Available

We are pleased to announce that Mitsubishi Tanabe Pharma Corp. has agreed to license Y-27632 to Sigma-Aldrich Research Biochemicals Inc.-"SARBI"(1 Strathmore Road, Natick, Massachusetts 01760, U.S.A.), EMD Chemicals Incorporated-"EMD", which is a successor of Calbiochem-Novabiochem Corp. (10394 Pacific Center Court, San Diego,CA 92121, U.S.A.), Wako Pure Chemical Industries, Ltd.-"Wako" (1-2, Doshomachi 3-Chome, Chuo-ku, Osaka 540-8605 Japan), and NACALAI TESQUE, INC.-"NACALAI"(Nijo Karasuma, Nakagyo-ku Kyoto 604-0855 Japan) as a research reagent.
Y-27632 is a highly potent, cell-permeable and selective inhibitor of Rho-associated coiled-coil forming protein kinases (ROCK). The decision to commercialize Y-27632 reflects our commitment to maximize the availability of the compound for research. For more information on how to obtain this compound from SARBI, EMD, Wako, and NACALAI, please visit their website

at: http://www.sigmaaldrich.com/sigma-aldrich/home.html(SARBI)
at: http://www.merckbiosciences.com/home.asp (EMD)
at: http://wako-chem.co.jp/english/(Wako)
at: http://www.nacalai.co.jp/en/index.html(NACALAI)